The Association Between Beta-blocker and Renin–Angiotensin System Inhibitor Use After Heart Failure With Reduced Ejection Fraction Hospitalization and Outcomes in Older Patients

• Published in: Journal of cardiac failure 2023-04, Vol.29 (4), p.434-444
• Main Authors: Gilstrap, LAUREN, SOLOMON, NICOLE, CHISWELL, KAREN, JAMES O'MALLEY, A., SKINNER, JONATHAN S., FONAROW, GREGG C., BHATT, DEEPAK L., Yancy, CLYDE W., DEVORE, ADAM D.
• Format: Article
• Language: English
• Subjects: Adrenergic beta-Antagonists - therapeutic use; Aged; Angiotensin Receptor Antagonists - pharmacology; Angiotensin Receptor Antagonists - therapeutic use; beta-blocker; Heart failure; Heart Failure - drug therapy; Heart Failure - epidemiology; Hospitalization; Humans; Medicare; outcomes; RASi; Renin-Angiotensin System; Stroke Volume; United States; Ventricular Dysfunction, Left - drug therapy
• ISSN: 1071-9164; 1532-8414
• DOI: 10.1016/j.cardfail.2022.11.010

Beta-blockers (BB) and renin–angiotensin system inhibitors (RASi) are foundational for the treatment of heart failure with reduced ejection fraction (HFrEF). However, given the increased risk of side effects in older patients, uncertainty remains as to whether, on net, older patients benefit as much as the younger patients studied in trials. Using the Get With The Guidelines–Heart Failure registry linked with Medicare data, overlap propensity weighted Cox proportional hazard models were used to examine the association between BB and RASi use at hospital discharge and 30-day and 1-year outcomes among patients with HFrEF. Among the 48,711 patients (aged ≥65 years) hospitalized with HFrEF, there were significant associations between BB and/or RASi use at discharge and lower rates of 30-day and 1-year mortality, including those over age 85 (30-day hazard ratio 0.56, 95% confidence interval 0.45–0.70; 1-year hazard ratio 0.69, 95% confidence interval 0.61–0.78). In addition, the magnitude of benefit associated with BB and/or RASi use after discharge did not decrease with advancing age. Even among the oldest patients, those over age 85, with hypotension, renal insufficiency or frailty, BB and/or RASi use at discharge was still associated with lower 1-year mortality or readmission. Among older patients hospitalized with HFrEF, BB and/or RASi use at discharge is associated with lower rates of 30-day and 1-year mortality across all age groups and the magnitude of this benefit does not seem to decrease with advancing age. These data suggest that, absent a clinical contraindication, BB and RASi should be considered in all patients hospitalized with HFrEF before or at hospital discharge, regardless of age. [Display omitted]